

Express Mail No.: <u>EL 501 636 857 US</u>

P#7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Application of: Schneider et al.

FEB 13 2001

Application No.: 09/305,084

. TO TO YOU

Filed: May 4, 1999

Examiner: A. Harris

Group Art Unit: 1642

TECH CENTER 1600/2900

CANCER TREATMENT WITH

ENDOTHELIN RECEPTOR

ANTAGONISTS

Attorney Docket No.: 5914-080-999

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

For:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references (**EK** and **EL**) listed on the attached revised form PTO-1449 entitled "List of References Cited by Applicant". Copies of references **EK** and **EL** are being submitted herewith.

Pursuant to 37 C.F.R. § 1.97(a), it is hereby stated that this Indoemation Disclosure Statement is being filed before the believed mailing date of a first Office Action on the merits, and that no fee is believed to be due, as provided under 37 C.F.R. § 1.97(b)(3).

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art". As an alternative, Applicants submit herewith several pages of a "revised form PTO-1449" entitled "List of References Cited" instead of "List of Prior Art Cited".

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(3) and 37 C.F.R. § 1.97(c) and (e), it is estimated that no fee is due. However, should the Patent Office determine otherwise, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date February 8, 2001

30.742

Laura A. Coruzzi

Reg. No.)

PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, New York 10036-2711 (212) 790-9090

Enclosure